<DOC>
	<DOC>NCT00575588</DOC>
	<brief_summary>Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.</brief_summary>
	<brief_title>52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed with type 2 diabetes, Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1, HbA1c &gt;6.5% and â‰¤10.0% Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar nonketonic coma, Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>DPP-4 Inhibitors</keyword>
	<keyword>HbA1c</keyword>
	<keyword>incretins</keyword>
</DOC>